JP2022522547A5 - - Google Patents

Info

Publication number
JP2022522547A5
JP2022522547A5 JP2020541718A JP2020541718A JP2022522547A5 JP 2022522547 A5 JP2022522547 A5 JP 2022522547A5 JP 2020541718 A JP2020541718 A JP 2020541718A JP 2020541718 A JP2020541718 A JP 2020541718A JP 2022522547 A5 JP2022522547 A5 JP 2022522547A5
Authority
JP
Japan
Prior art keywords
conjugate according
antibody conjugate
cancer
alkyl
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522547A (ja
JP7664045B2 (ja
Filing date
Publication date
Priority claimed from KR1020200027373A external-priority patent/KR102503143B1/ko
Application filed filed Critical
Priority claimed from PCT/KR2020/003100 external-priority patent/WO2020180121A1/ko
Publication of JP2022522547A publication Critical patent/JP2022522547A/ja
Publication of JP2022522547A5 publication Critical patent/JP2022522547A5/ja
Priority to JP2025009671A priority Critical patent/JP2025076435A/ja
Application granted granted Critical
Publication of JP7664045B2 publication Critical patent/JP7664045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541718A 2019-03-06 2020-03-05 ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用 Active JP7664045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009671A JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190025987 2019-03-06
KR10-2019-0025987 2019-03-06
KR1020200027373A KR102503143B1 (ko) 2019-03-06 2020-03-04 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR10-2020-0027373 2020-03-04
PCT/KR2020/003100 WO2020180121A1 (ko) 2019-03-06 2020-03-05 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009671A Division JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用

Publications (3)

Publication Number Publication Date
JP2022522547A JP2022522547A (ja) 2022-04-20
JP2022522547A5 true JP2022522547A5 (https=) 2023-03-13
JP7664045B2 JP7664045B2 (ja) 2025-04-17

Family

ID=72337989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541718A Active JP7664045B2 (ja) 2019-03-06 2020-03-05 ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用
JP2025009671A Pending JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009671A Pending JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用

Country Status (6)

Country Link
US (1) US20220339291A1 (https=)
EP (1) EP3936150A4 (https=)
JP (2) JP7664045B2 (https=)
BR (1) BR112021017303A2 (https=)
MX (1) MX2021010453A (https=)
WO (1) WO2020180121A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
KR102847348B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법
AU2016359230B2 (en) 2015-11-25 2020-04-23 Ligachem Biosciences Inc. Conjugates comprising self-immolative groups and methods related thereto
AU2016359235B2 (en) 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
CN112601555A (zh) 2018-05-09 2021-04-02 乐高化学生物科学股份有限公司 与抗cd19抗体药物结合物相关的组合物和方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
WO1988007086A1 (en) 1987-03-20 1988-09-22 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
EP0305500B1 (en) 1987-03-20 1994-11-09 Creative Biomolecules, Inc. Process for the purification of recombinant polypeptides
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
KR101512203B1 (ko) * 2006-11-10 2015-04-15 가부시키가이샤 리부텍쿠 ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
US8017118B2 (en) * 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
KR101461706B1 (ko) * 2011-04-04 2014-11-18 한국생명공학연구원 Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제
MX393973B (es) 2011-05-08 2025-03-24 Legochem Biosciences Inc Conjugados de proteína-agente activo y método para su preparación.
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
AU2016359235B2 (en) * 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
HUE056289T2 (hu) * 2017-02-08 2022-02-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
KR101966672B1 (ko) 2017-03-22 2019-04-09 신화인터텍 주식회사 파장 변환 부재 및 이를 포함하는 디스플레이 장치
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
WO2018182341A1 (ko) * 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
KR102286050B1 (ko) 2017-06-23 2021-08-03 현대자동차주식회사 차량 네트워크에서 진단 오류 방지를 위한 방법 및 장치
KR20190018400A (ko) * 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
CN111278860B (zh) * 2017-09-08 2024-03-29 Y生物股份有限公司 抗人dlk1的抗体及其用途
KR20200084802A (ko) * 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2022522547A5 (https=)
JP2021523232A5 (https=)
JP2021063058A5 (https=)
JP2023531252A5 (https=)
EP4321180A1 (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
TWI808931B (zh) 包含分支連接子之抗體-藥物結合物及與其相關之方法
JP2019503980A5 (https=)
AU2016279051B2 (en) Delivery systems for controlled drug release
HRP20240795T1 (hr) Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
JP2019503979A5 (https=)
JP2019503981A5 (https=)
KR102187410B1 (ko) 치료제를 전달하기 위한 pH-민감성 링커
TW201729844A (zh) 關於抗-cd19抗體藥物共軛物之組合物及方法
TW201722480A (zh) 關於抗-egfr抗體藥物共軛物之組合物及方法
CN120076831A (zh) 抗ror1抗体和抗体缀合物、包含抗ror1抗体或抗体缀合物的组合物、以及制备和使用抗ror1抗体和抗体缀合物的方法
AU2020233532B2 (en) Antibody-drug conjugates including antibody against human DLK1, and use thereof
EP3936150A1 (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof
KR20160068738A (ko) 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
JP2024160336A (ja) トリス構造を有するリンカーを含むリガンド―薬物複合体
JP2026510495A (ja) ヒトｌ１ｃａｍに対する抗体を含む抗体－薬物コンジュゲートおよびその使用
JP7038663B2 (ja) 環中に少なくとも２個の（－ｃｈ２－ｃｈ２－０－）単位を含むリンカーを含むコンジュゲート及びコンジュゲート試薬
JP2025511705A5 (https=)
RU2021128538A (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
EP3770170A1 (en) Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
KR102501394B1 (ko) 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체